Monday, April 25, 2016 9:26:22 AM
HTTP://theassociationofphysicians.org.uk/files/APAM_2016_Programme.pdf
9:30 a.m.
12) Trovax® And Cyclophosphamide InduceAnti-Tumour Immune ResponsesThat CorrelateWith Prolonged
Survival Of End-Stage Colorectal Cancer Patients
Godkin, A; Pembroke, T; Gallimore, A; Scurr, M
The cytotoxic response to cancer is counteracted by tumour-induced immunosuppression. 54 colorectal cancer patients with
inoperable metastatic disease were randomized to a virus vaccine expressing an oncofetal antigen +/-
cyclophophosphamide to counteract immune regulation. The results of this phase I/II trial demonstrate improved outcome
corresponding to tumour-directed T cell responses.
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM